WASHINGTON —The Food and Drug Administration on Friday approved Roche's injectable eye drug Lucentis for a new use in treating a diabetes-related condition that can cause blindness.
The agency cleared the drug for diabetic macular edema, a condition that causes swelling and blurred vision in patients with diabetes. In 2010, 3.9 million adults with diabetes reported vision problems, according to the FDA.
Lucentis is currently marketed for wet, age-related macular degeneration, the leading cause of blindness among the elderly. The drug has been facing new competition in that market from Regeneron Pharmaceutical's Eylea, which is cheaper and can be administered with fewer injections.
Side effects with Lucentis include bleeding around the tissue that lines the eyelids and increased pressure on the eyes.
Lucentis is manufactured by Roche's Genentech unit
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
One person will win a three-year lease on a 2013 Honda Civic Lx Sedan automatic.
Click to see the latest mugshots, plus this week's wanted fugitives.
This feature packed upgrade brings you faster performance, easier navigation, and stunning improvements to photos, video and readability.
Latest Health Headlines
More than 6% of adolescents reported using psychotropic medications during the past month, according to a survey released Wednesday by the Centers for Disease Control and Prevention.